Literature DB >> 19262387

Measurement tools for gastrointestinal symptoms in radiation oncology.

Catharine M L West1, Susan E Davidson.   

Abstract

PURPOSE OF REVIEW: To review the use of measurement tools for reporting gastrointestinal toxicity in radiation oncology to highlight recent findings of potential interest to those involved in the treatment of tumors in the pelvis, assessment of survivorship issues or management of bowel effects. RECENT
FINDINGS: Multiple measurement tools are being used in radiation oncology studies involving both clinician and patient-reported outcomes. The increasing availability of accurate data on radiation doses and dose-volumes to normal tissues is enabling identification of critical areas where dose should be reduced to minimize organ damage.
SUMMARY: Measurement tools for gastrointestinal symptoms are important to highlight therapeutic benefit for the expanding investigations of treatment intensification approaches and methods for toxicity reduction. The increasing use of the CTCAEv3 scales is a step forward, but further research is required to refine the system and improve its ease of use within routine clinical practice.

Entities:  

Mesh:

Year:  2009        PMID: 19262387     DOI: 10.1097/SPC.0b013e328325d18d

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  9 in total

1.  Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care: a decade of progress.

Authors:  Matthew A Ciorba
Journal:  Curr Opin Support Palliat Care       Date:  2016-06       Impact factor: 2.302

Review 2.  The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis.

Authors:  Y-H Wang; N Yao; K-K Wei; L Jiang; S Hanif; Z-X Wang; C-X Pei
Journal:  Eur J Clin Nutr       Date:  2016-06-22       Impact factor: 4.016

3.  Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists.

Authors:  C C Henson; S E Davidson; A Lalji; R P Symonds; R Swindell; H J N Andreyev
Journal:  Support Care Cancer       Date:  2011-11-13       Impact factor: 3.603

4.  Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy?

Authors:  I D White; H Allan; S Faithfull
Journal:  Br J Cancer       Date:  2011-09-06       Impact factor: 7.640

5.  Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer.

Authors:  H Jervoise N Andreyev; Susan E Davidson; Catherine Gillespie; William H Allum; Edwin Swarbrick
Journal:  Gut       Date:  2011-11-04       Impact factor: 23.059

Review 6.  Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults.

Authors:  Qurrat U van den Blink; Kate Garcez; Caroline C Henson; Susan E Davidson; Claire E Higham
Journal:  Cochrane Database Syst Rev       Date:  2018-04-23

7.  Radiation-induced bowel injury: the impact of radiotherapy on survivorship after treatment for gynaecological cancers.

Authors:  S Kuku; C Fragkos; M McCormack; A Forbes
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

8.  Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy.

Authors:  Caroline C Henson; Susan E Davidson; Yeng Ang; Chris Babbs; John Crampton; Mark Kelly; Simon Lal; Jimmy K Limdi; Greg Whatley; Ric Swindell; Wendy Makin; John McLaughlin
Journal:  Support Care Cancer       Date:  2013-03-21       Impact factor: 3.603

9.  Randomised clinical trial of a gastrointestinal care bundle to reduce symptoms in patients with pelvic cancer undergoing chemoradiotherapy.

Authors:  Katherine L White; Caroline C Henson; Mark Hann; Martin Eden; Sorrel T Burden; Simon Lal; Susan E Davidson; John T McLaughlin
Journal:  BMJ Open Gastroenterol       Date:  2020-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.